The project management is responsible for the content of the information provided.
This project, funded by Gebert Rüf Stiftung, is supported by the following project partners: HES-SO Valais/Wallis; The Ark; Eqlosion; aeChem; Simulton
Données de projet
Numéro du projet: GRS-053/19
Subside accordé: CHF 150'000
Durée: 09.2019 - 09.2020
Champs d'activité: First Ventures, seit 2018
Direction du projet
Rte du Rawil 64
1950 Sitten 2 (Schweiz)
- cindy.weber@hevs. ch
Drug development is strongly accompanied by diagnostic tests to identify disease and to monitor the effectiveness of therapy. More than 50 % of treatment decisions are based on the results of diagnostic procedures. Unfortunately, an important aspect in developing countries, but also in decentralised laboratories or small hospitals in developed countries, is that they often do not have access to basic diagnostic systems, insufficiently trained personnel and not enough funding for expensive analytical equipment. The idea of the LifeCellAgglutination (LCA) diagnostic system is to simplify the diagnostic process for doctors, by developing and implementing a daily in-vitro diagnostic system for the quantification of human blood cells, and thereby improve the quality of life of the affected persons. The test is based on an antigen-antibody reaction between specific beads and the target cells, in this case the immune system relevant T cells from human whole blood. LCA serves as a fast, simple, sensitive/specific, low-cost system. No complex sample preparation is necessary, with only 5 µL patients whole blood we can obtain the result in less than 5 minutes. In future tests the system can be modified in this way, that other cell populations or disease specific markers can measured and so creating a diagnostic platform.
Quelles sont les particularités de ce projet?
An analysis of the need shows that despite the advanced techniques used today in medical laboratories, such a fast, simple and cost-effective analytical alternative is profitable in many aspects.
The innovation of this test is that through many small but important criteria, a system can be created that can compete qualitatively and quantitatively with today's more expensive method. The advantage of this diagnostic method is that it is much cheaper than the method used today, not only because of the relatively low material costs, but also because of the acquisition costs, maintenance costs and support costs. In addition, it differs from other competitors in that it is significantly faster and does not require highly qualified personnel due to its simple implementation. This means that no lengthy and complex sample preparation times are required for this diagnostic test. The diagnostic test is developed as a so-called one-step test in which 5 µL whole blood and a specific bead suspension are completely sufficient to quantitatively determine the living blood cells. Due to its versatility, the test can be designed in such a way that it will later serve as a so-called platform for various diseases.
Due to the fast reaction time, there is no waiting time for the results. Any changes in the blood count can thus be detected directly in order to carry out further specific examinations in order to make an exact diagnosis. This also includes that, depending on the change, various causes can be excluded right from the start. This not only simplifies further decisions by specialists, but can also be vital for patients through early detection of diseases.
The principle and feasibility has already been proven in laboratory tests. In addition, successful development steps and optimizations of the test system, such as the one-step analysis principle, have already been successfully tested. In additional experiments, the interaction with other cells or the beads alone (specificity) was clearly excluded. In addition to the specificity, a sensitivity of 123 cells/µL whole blood was already achieved in the first tests.
The project is to be given more weight in the scientific, business and marketing aspects by actively strengthening the partnership, evaluating the IP in detail and pursuing later approval by regulatory affairs.
Revue de presse
Zoom sur trois start-up qui mettent en lumière le valais innovant!
, Blog The Ark, 25.07.2019CHF 450’000 for Foodtech, cleantech and Biotech projects
, Startup ticker, 19.07.2019Un soutien de 150'000 francs pour un projet de diagnostic médical
, AGEFI, 17.07.2019Sitten: Förderung für ein Projekt im Bereich der medizinischen Diagnose
, RRO, 17.07.2019
«LifeCellAgglutination diagnostic simple et rapide», Beney, Alexandre, Le Nouvelliste, Nr. 163, p. 3., 17.07.2019Deux Diplomées du Master Life sciences récompensées
, HES-SO, 15.07.2019
Personnes participant au projet
Dernière mise à jour de cette présentation du projet 11.02.2020